Business
Mesoblast now expects to release Ryoncil ruling on Monday – Stockhead
Mesoblast is in a trading halt, but doesn’t expect to announce the FDA’s decision on Ryoncil until Monday Approval of the stem cell treatment to treat pediatric…
Link copied toclipboard
- Mesoblast is in a trading halt, but doesn’t expect to announce the FDA’s decision on Ryoncil until Monday
- Approval of the stem cell treatment to treat pediatric graft-versus-host disease would be transformative for the company
- A reason for the delay wasn’t given
Mesoblast (ASX:MSB) shareholders have a few more sleepless nights ahead of them.
The closely watched biotech went into a trading halt this morning in relation to the US Food and …
Continue Reading
-
General22 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News22 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland
-
Noosa News21 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
Business23 hours ago$10,000 invested in ANZ shares 5 years ago is now worth…